Premium
Nanoencapsulation increases (−)‐epigallocatechin gallate stability and its cellular bioavailability in macrophages
Author(s) -
Wang Shu,
Zhang Jia,
Sun Ming,
Fan Zhaoyang
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.646.5
Subject(s) - bioavailability , epigallocatechin gallate , nanocarriers , chemistry , high performance liquid chromatography , gallate , catechin , pharmacology , chromatography , antioxidant , biochemistry , polyphenol , medicine , drug delivery , organic chemistry , nuclear chemistry
Atherosclerotic cardiovascular disease is the leading cause of death in U.S. Macrophages are major cells responsible for atherosclerotic lesion development. (−)‐Epigallocatechin gallate (EGCG) abundant in green tea is valuable for the prevention and treatment of atherosclerosis. But low levels of stability and bioavailability limit its application in human. We encapsulated EGCG into biocompatible and biodegradable nanocarriers to increase its stability and cellular bioavailability. The stability of nanoencapsulated EGCG and native EGCG was measured at pH 7.2 at 4 °C and 25 °C. Nanoencapsulated EGCG was separated from nonencapsulated EGCG using a Sephadex™ G‐25 column. Total and nanoencapsulated EGCG was measured using a high‐performance liquid chromatography (HPLC) system. EGCG uptake by THP‐1 derived macrophages was measured using the same HPLC system. Nanoencapsulation significantly increased EGCG stability and its uptake by macrophages compared to native EGCG. This innovation portends a potential breakthrough in the prevention and treatment of atherosclerosis by using natural compounds with minimized immunogenicity and side‐effects. Grant Funding Source : NIH 1R15AT007013‐01